GLPwatch

The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells.

Biochem Biophys Res Commun · 2014

Last updated 2026-05-28

In lab tests, a GLP-1 drug (exendin-4) increased the activity of a protein called PPARγ in human blood vessel cells by about 20% compared to untreated cells. The effect peaked 12 hours after treatment, and blocking a related signaling pathway stopped this increase. The findings suggest GLP-1 may help reduce inflammation in blood vessels through this mechanism.

AI summary of the abstract below.

JournalBiochem Biophys Res Commun, 2014
Citations14
Relative citation ratio0.46
NIH percentile27
Molecules

Abstract

Recent studies have suggested glucagon-like peptide-1 (GLP-1) signaling to exert anti-inflammatory effects on endothelial cells, although the precise underlying mechanism remains to be elucidated. In the present study, we investigated whether PPARγ activation is involved in the GLP-1-mediated anti-inflammatory action on endothelial cells. When we treated HUVEC cells with 0.2ng/ml exendin-4, a GLP-1 receptor agonist, endogenous PPARγ transcriptional activity was significantly elevated, by approximately 20%, as compared with control cells. The maximum PPARγ activity enhancing effect of exendin-4 was observed 12h after the initiation of incubation with exendin-4. As H89, a PKA inhibitor, abolished GLP-1-induced PPARγ enhancement, the signaling downstream from GLP-1 cross-talk must have been involved in PPARγ activation. In conclusion, our results suggest that GLP-1 has the potential to induce PPARγ activity, partially explaining the anti-inflammatory effects of GLP-1 on endothelial cells. Cross-talk between GLP-1 signaling and PPARγ activation would have major impacts on treatments for patients at high risk for cardiovascular disease.

Verbatim abstract via PubMed 25109805 ↗